Alejandro Berkovits
Santiago, RM, Chile
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 07, 2025
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 08, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2025
Consensus for Oncology Genetic Counseling and Molecular Diagnosis: The Punta Arenas Statement
Journal: Revista medica de Chile
Published: August 02, 2024
Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience.
Journal: Journal of personalized medicine
Published: December 23, 2021
Proteogenomic analysis in an early onset diffuse gastric cancer patient revealed alterations in PIK3R1, TP53, SMAD4 and a potential role of the PI3K-AKT and EGFR pathways: a case report.
Journal: Journal of gastrointestinal oncology
Published: November 17, 2021
Double hit lymphoma: from biology to therapeutic implications.
Journal: Expert review of hematology
Published: May 12, 2016
Isolated factor X deficiency in chronic myelomonocytic leukemia: Report of one case
Journal: Revista medica de Chile
Published: September 08, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026